Northwest Investment Counselors LLC Invests $193,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Northwest Investment Counselors LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, HoldingsChannel reports. The fund bought 184 shares of the biopharmaceutical company’s stock, valued at approximately $193,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Park Avenue Securities LLC increased its position in shares of Regeneron Pharmaceuticals by 9.2% in the first quarter. Park Avenue Securities LLC now owns 1,671 shares of the biopharmaceutical company’s stock valued at $1,609,000 after acquiring an additional 141 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 9.4% during the 1st quarter. International Assets Investment Management LLC now owns 736 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 63 shares during the last quarter. Ballentine Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 37.7% during the 1st quarter. Ballentine Partners LLC now owns 1,040 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 285 shares in the last quarter. Range Financial Group LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $229,000. Finally, Gateway Investment Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 13.7% in the 1st quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock valued at $1,287,000 after buying an additional 161 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $14.67 on Monday, reaching $976.01. 343,701 shares of the company’s stock were exchanged, compared to its average volume of 495,519. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a fifty day moving average of $1,109.58 and a 200-day moving average of $1,041.01. The company has a market capitalization of $107.54 billion, a price-to-earnings ratio of 28.85, a PEG ratio of 3.45 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.79 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Royal Bank of Canada boosted their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, Argus boosted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,116.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.